the company was under the radar and oversold for a long time due to the CRL last year. After the long-awaited approval, it still hasn't leaked out what this event means for the future of cancer therapy. The media is not reporting on it, so there is no hype. If a partnership with Merck is announced (or another pharmaceutical giant), it will soon be leaked to the masses. FYI: Anktiva has a 71% success rate in the treatment of bladder cancer (WITHOUT adverse events), compared to Merck's Keytruda, the current standard therapy, with only 42% and sometimes severe side effects and a shorter duration of action
Why did you sell at this point? Uptrend on short timeframe is still in tact. The saucer is only just being filled and resistance is still to come 🙂 In addition, a cooperation is to be published ... @ShovelStocks certainly knows more about it.
